Plant-touching vs ancillary investment

Plant-touching vs ancillary at a glance

Factor	Plant-touching business	Ancillary business
Examples	Dispensary, cultivation, manufacturing, distribution, delivery, testing lab	Packaging, equipment, software, security, staffing, consulting, real estate, lending
State cannabis license	Required	Not required, though some states register vendors or review contracts
Owner approval	Background and financial review of owners and many investors	None, unless the contract gives profit share or control
Federal status	Adult-use marijuana is Schedule I; state-licensed medical is Schedule III since April 2026	Lawful goods and services, with some aiding-and-abetting and banking friction
280E	Applies to adult-use activity	Does not apply
SBA and bank loans	Ineligible	Case by case; often ineligible if built for the cannabis market
Major exchange listing	Generally unavailable	Available; cannabis REITs and lenders are listed
Federal bankruptcy	Generally unavailable	Sometimes available; courts look at the revenue source
What protects margins	License caps, zoning, location	Product, contracts, switching costs; rarely regulation
Main risk	Regulatory, tax, wholesale price	Customer credit, concentration, low barriers to entry
Exit	Sale needs regulator approval; narrow buyer pool	Ordinary sale; wider buyer pool

What is the difference between plant-touching and ancillary?

The line is whether the business possesses or takes title to marijuana. If it does, it needs a state license, and everything about owning it, financing it, taxing it, and selling it runs through that license. If it does not, it is an ordinary company with unusual customers.

The line can blur. A management company paid a share of a dispensary’s profit, a brand that licenses its name for a percentage of sales, or a lender with a right to convert into equity may be treated by the regulator as an owner. Washington makes anyone entitled to a share of profits a true party of interest, and California requires disclosure of financial interest holders. See true party of interest and financial interest rules. The business models on each side are described in cannabis business models explained.

How does tax treatment differ?

This is the largest single financial difference. Section 280E denies all deductions and credits, other than cost of goods sold, to a business trafficking in a Schedule I or II substance. Adult-use marijuana is still Schedule I. The 28 April 2026 order moved marijuana under a state medical license to Schedule III, which takes that activity out of 280E going forward; dual operators apportion.

Illustrative: two companies each earn $500,000 before tax on $3,000,000 of revenue. The adult-use retailer has $1,300,000 of operating expenses that 280E disallows, so it is taxed on $1,800,000 of gross profit. At 21% that is $378,000 of federal tax, leaving $122,000. The packaging supplier deducts its expenses, pays 21% of $500,000, or $105,000, and keeps $395,000. Same pre-tax profit; more than three times the after-tax cash.

That is why the same multiple cannot be applied to both. The license-by-license picture is in 280E by license type.

Financing, banking, and capital markets

Debt. Plant-touching businesses are excluded from SBA 7(a) and 504 lending by SOP 50 10 8. Ancillary businesses are not automatically eligible either. Earlier SBA guidance used a defined term, the indirect marijuana business, for companies selling to licensees; the current SOP drops the term but keeps a broad test that excludes products or services used in connection with illegal activity unless that use is “completely outside of the Applicant’s intended market”. A general supplier with incidental cannabis customers stands very differently from a company built to serve growers. Detail is in why SBA and banks are unavailable.

Equity and exchanges. The NYSE and Nasdaq will not list a company whose activities violate federal law, as Akerman summarised in May 2026. Ancillary companies, including cannabis-focused REITs and lenders, can list. For a founder that means a wider set of eventual acquirers and investors, including institutions that cannot hold plant-touching assets.

Banking. Ancillary companies usually keep ordinary bank accounts, though banks may still ask about cannabis-derived revenue. Licensees bank under FinCEN’s 2014 guidance with a limited set of institutions; see cannabis banking status.

Does ancillary mean lower risk?

It means different risk. An ancillary company avoids license, 280E, and approval risk. It takes on the credit risk of customers who carry all three.

The public record shows it. Innovative Industrial Properties, a listed cannabis landlord, described defaulted tenants, security deposits applied to unpaid rent, and a tenant receivership expected to run through the end of 2026 in its second-quarter 2026 report. When wholesale prices fall, operators stretch vendors first. An equipment or packaging supplier with 60% of receivables from three growers in an oversupplied state has cannabis risk, whatever its tax return says.

Ancillary companies also lack the moat that makes some licenses valuable. A capped-city dispensary is protected by law from new competitors. A cannabis software or packaging firm competes with anyone who wants to enter, including large general-market vendors once federal law eases. License scarcity is explained in license value in capped vs uncapped states.

Bankruptcy access is better but not certain. Licensed operators generally cannot use chapter 7 or 11. For ancillary firms the courts look at the revenue. The Ninth Circuit confirmed a plan for a landlord with a marijuana tenant in Garvin, and later commentary sees more room for indirect businesses than for operators. A Colorado court reached the opposite result for hydroponics retailer Way to Grow, a case covered in receiverships and the bankruptcy gap.

How do valuation and exit compare?

Plant-touching businesses are priced on after-tax earnings, license scarcity, and state conditions. Viridian Capital reported larger public operators at a median 5.1x enterprise value to 2026 EBITDA in November 2025, and private sales usually price below public comparables. A sale needs regulator approval of the buyer, which adds months and narrows the pool to approvable buyers.

Ancillary businesses are valued like their non-cannabis peers, a packaging company against packaging companies, a software firm on recurring revenue, then adjusted for customer concentration and receivable quality. The sale is an ordinary private transaction with no regulator in the middle, unless the company holds contracts that make it a disclosed party. The license-type hub for ancillary cannabis businesses covers packaging, equipment, software, and real estate holdings in more depth.

Rescheduling cuts both ways. If adult-use marijuana later leaves Schedule I, operators gain the most, because 280E falls away. Ancillary firms gain indirectly, through healthier customers, and may lose some protection as mainstream competitors enter. Scenarios are in how rescheduling would affect valuation.

Which fits you?

Plant-touching tends to fit buyers who:

• Want an asset protected by a license cap or a zoning-limited location.
• Can pass state background and financial review, and whose investors can too.
• Have operating experience, or will hire it, in retail, cultivation, or manufacturing.
• Can fund the purchase without SBA or bank debt and can live with 280E on adult-use income.
• Accept that the exit will need regulator approval and a narrower buyer pool.

Ancillary tends to fit buyers who:

• Cannot or do not want to be a disclosed owner of a licensee. Non-citizens face particular exposure; see immigration consequences for non-citizen owners.
• Bring a skill from another industry, such as packaging, HVAC, software, or lending.
• Want ordinary tax treatment and conventional financing options.
• Are prepared to underwrite customers’ credit and diversify away from any one state’s market cycle.

Questions to ask of any ancillary target: What share of revenue comes from the top five customers? What is the receivables aging? Is any fee tied to a licensee’s revenue or profit? Does the company touch product at any point, for example in packaging or transport? Would a bank or the SBA see cannabis as the intended market?

Whether either type suits a given person is an individual decision. General considerations are in is a cannabis business a good investment?.

This comparison is educational. It is not investment, tax, or legal advice, and it does not recommend any security or company.